top of page
Biosciences
Offspring
Insights & Updates
Four Reasons Antibody Programs Fail Before They Reach Patients
The most successful translational strategies increasingly focus on generating human-relevant evidence earlier, when development teams still have the opportunity to refine candidate selection, optimize trial design, and reduce uncertainty before major investments are made.
Featured
Search
Beyond the Checklist: Strategic TMAs for Definitive Tissue Cross-Reactivity
Executed strategically, using a specifically curated Tissue Microarray (TMA), TCR studies provide a rich dataset that provides "Deep Insights" into novel therapeutic antibodies, their comparative performance, and their associated risk in human patient trials.
evadanielson55
May 264 min read
The Validation Gauntlet: Multi-Modal Framework for Fit-for-Purpose IHC
A detailed examination of the technical pillars of assay validation, from tissue integrity screening and antibody selection to antibody validation with ISH and isPLA
evadanielson55
Apr 285 min read
Operationalizing Translational Success: Why the 5R Framework Demands a Tissue-First Approach
For over a decade, the pharmaceutical industry has universally admired the structured translational frameworks pioneered by industry leaders. When AstraZeneca instituted the "5R Framework" (Right Target, Right Tissue, Right Safety, Right Patient, Right Commercial) and Pfizer deployed their "Three Pillars of Survival" (now the SOCA paradigm), the results were undeniable. AstraZeneca drove their Phase III success rate from a dismal 4% to 19% (1), while Pfizer saw a tenfold impr
evadanielson55
Apr 144 min read
Validating CNS Therapeutics
Human Tissue Analysis in CNS drug development helps to bridge the translational gap and de-risk clinical development. New research on Alzheimers Disease, Palsy, Parkinsons, Multi System Atrophy and more offer insights into treatment development.
evadanielson55
Jan 274 min read
bottom of page